Eagle Historical Income Statement

EGRX Stock

USD 4.41 0.01 0.23%

Historical analysis of Eagle Pharmaceuticals income statement accounts such as Selling General Administrative of 118.5 M or Total Revenue of 382.3 M can show how well Eagle Pharmaceuticals performed in making a profits. Evaluating Eagle Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eagle Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eagle Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eagle Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

About Eagle Income Statement Analysis

Eagle Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eagle Pharmaceuticals shareholders. The income statement also shows Eagle investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Eagle Pharmaceuticals Income Statement Chart

Eagle Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Eagle's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eagle Pharmaceuticals revenue and expense. Eagle Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Research Development Net Income Applicable To Common Shares

Total Revenue

Total revenue comprises all receipts Eagle Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eagle Pharmaceuticals. It is also known as Eagle Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Eagle Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.6M	4.0M	4.7M	4.9M
Depreciation And Amortization	3.8M	12.0M	13.8M	14.5M

Interest Expense Depreciation And Amortization

Eagle Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Non Recurring	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.95	0.95	0.92	0.9	0.93	0.73	0.72	0.55	0.78	0.94	0.76	0.77	0.66	0.52	0.81	0.26	0.46	-0.83	0.8	0.4	-0.01	-0.89	0.93	0.72
Interest Expense	0.95		0.92	0.86	0.85	0.88	0.65	0.66	0.55	0.72	0.89	0.74	0.69	0.51	0.43	0.81	0.11	0.35	-0.79	0.8	0.4	0.03	-0.93	0.85	0.66
Selling General Administrative	0.95	0.92		0.96	0.96	0.97	0.81	0.8	0.7	0.85	0.95	0.87	0.83	0.48	0.6	0.78	0.2	0.56	-0.77	0.77	0.43	0.19	-0.89	0.8	0.62
Total Revenue	0.92	0.86	0.96		1.0	0.99	0.91	0.91	0.74	0.94	0.99	0.88	0.93	0.46	0.77	0.68	0.34	0.73	-0.72	0.66	0.33	0.33	-0.88	0.78	0.62
Gross Profit	0.9	0.85	0.96	1.0		0.99	0.92	0.91	0.76	0.94	0.98	0.89	0.93	0.43	0.77	0.67	0.32	0.73	-0.71	0.66	0.32	0.35	-0.87	0.76	0.6
Other Operating Expenses	0.93	0.88	0.97	0.99	0.99		0.86	0.85	0.79	0.89	0.98	0.9	0.87	0.44	0.7	0.68	0.33	0.66	-0.73	0.66	0.4	0.27	-0.88	0.78	0.61
Operating Income	0.73	0.65	0.81	0.91	0.92	0.86		1.0	0.6	0.99	0.88	0.76	1.0	0.35	0.93	0.51	0.31	0.9	-0.5	0.5	0.17	0.57	-0.71	0.6	0.47
Ebit	0.72	0.66	0.8	0.91	0.91	0.85	1.0		0.62	1.0	0.88	0.76	0.99	0.3	0.92	0.52	0.27	0.89	-0.49	0.5	0.17	0.61	-0.73	0.58	0.46
Research Development	0.55	0.55	0.7	0.74	0.76	0.79	0.6	0.62		0.63	0.69	0.89	0.58	-0.07	0.52	0.34	0.26	0.54	-0.36	0.32	0.43	0.41	-0.61	0.3	0.26
Ebitda	0.78	0.72	0.85	0.94	0.94	0.89	0.99	1.0	0.63		0.92	0.79	0.99	0.36	0.9	0.57	0.28	0.87	-0.55	0.56	0.2	0.55	-0.77	0.65	0.51
Cost Of Revenue	0.94	0.89	0.95	0.99	0.98	0.98	0.88	0.88	0.69	0.92		0.85	0.91	0.52	0.75	0.67	0.36	0.7	-0.73	0.66	0.34	0.26	-0.88	0.83	0.66
Total Operating Expenses	0.76	0.74	0.87	0.88	0.89	0.9	0.76	0.76	0.89	0.79	0.85		0.75	0.22	0.62	0.55	0.31	0.65	-0.6	0.53	0.44	0.29	-0.78	0.54	0.44
Income Before Tax	0.77	0.69	0.83	0.93	0.93	0.87	1.0	0.99	0.58	0.99	0.91	0.75		0.43	0.91	0.56	0.33	0.88	-0.56	0.54	0.17	0.51	-0.74	0.67	0.53
Total Other Income Expense Net	0.66	0.51	0.48	0.46	0.43	0.44	0.35	0.3	-0.07	0.36	0.52	0.22	0.43		0.26	0.51	0.46	0.18	-0.7	0.51	0.04	-0.47	-0.4	0.82	0.65
Net Income	0.52	0.43	0.6	0.77	0.77	0.7	0.93	0.92	0.52	0.9	0.75	0.62	0.91	0.26		0.17	0.51	0.98	-0.31	0.15	0.09	0.61	-0.49	0.42	0.33
Income Tax Expense	0.81	0.81	0.78	0.68	0.67	0.68	0.51	0.52	0.34	0.57	0.67	0.55	0.56	0.51	0.17		-0.22	0.11	-0.73	1.0	0.22	-0.03	-0.78	0.77	0.6
Selling And Marketing Expenses	0.26	0.11	0.2	0.34	0.32	0.33	0.31	0.27	0.26	0.28	0.36	0.31	0.33	0.46	0.51	-0.22		0.51	-0.38	-0.23	-0.17	-0.12	-0.18	0.35	0.33
Net Income From Continuing Ops	0.46	0.35	0.56	0.73	0.73	0.66	0.9	0.89	0.54	0.87	0.7	0.65	0.88	0.18	0.98	0.11	0.51		-0.26	0.09	0.09	0.63	-0.46	0.34	0.28
Non Operating Income Net Other	-0.83	-0.79	-0.77	-0.72	-0.71	-0.73	-0.5	-0.49	-0.36	-0.55	-0.73	-0.6	-0.56	-0.7	-0.31	-0.73	-0.38	-0.26		-0.72	0.02	0.27	0.85	-0.9	-0.64
Tax Provision	0.8	0.8	0.77	0.66	0.66	0.66	0.5	0.5	0.32	0.56	0.66	0.53	0.54	0.51	0.15	1.0	-0.23	0.09	-0.72		0.21	-0.04	-0.77	0.77	0.59
Interest Income	0.4	0.4	0.43	0.33	0.32	0.4	0.17	0.17	0.43	0.2	0.34	0.44	0.17	0.04	0.09	0.22	-0.17	0.09	0.02	0.21		-0.03	-0.15	0.12	0.05
Non Recurring	-0.01	0.03	0.19	0.33	0.35	0.27	0.57	0.61	0.41	0.55	0.26	0.29	0.51	-0.47	0.61	-0.03	-0.12	0.63	0.27	-0.04	-0.03		-0.15	-0.2	-0.16
Net Interest Income	-0.89	-0.93	-0.89	-0.88	-0.87	-0.88	-0.71	-0.73	-0.61	-0.77	-0.88	-0.78	-0.74	-0.4	-0.49	-0.78	-0.18	-0.46	0.85	-0.77	-0.15	-0.15		-0.82	-0.58
Reconciled Depreciation	0.93	0.85	0.8	0.78	0.76	0.78	0.6	0.58	0.3	0.65	0.83	0.54	0.67	0.82	0.42	0.77	0.35	0.34	-0.9	0.77	0.12	-0.2	-0.82		0.8
Extraordinary Items	0.72	0.66	0.62	0.62	0.6	0.61	0.47	0.46	0.26	0.51	0.66	0.44	0.53	0.65	0.33	0.6	0.33	0.28	-0.64	0.59	0.05	-0.16	-0.58	0.8

Click cells to compare fundamentals

Eagle Pharmaceuticals Account Relationship Matchups

Eagle Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	4.8M	3.8M	12.0M	13.8M	14.5M
Interest Expense	2.7M	2.6M	1.6M	4.0M	4.7M	4.9M
Selling General Administrative	74.0M	75.9M	66.8M	98.1M	112.8M	118.5M
Total Revenue	195.9M	187.8M	171.5M	316.6M	364.1M	382.3M
Gross Profit	135.0M	142.3M	129.4M	221.7M	254.9M	267.7M
Other Operating Expenses	174.1M	154.8M	168.8M	235.7M	271.0M	284.5M
Operating Income	21.8M	25.3M	(2.9M)	53.5M	61.5M	64.5M
Ebit	21.8M	25.3M	(2.9M)	53.5M	61.5M	64.5M
Research Development	36.8M	30.8M	51.3M	34.1M	39.2M	32.8M
Ebitda	29.3M	30.0M	847K	65.5M	75.3M	79.1M
Cost Of Revenue	60.9M	45.5M	42.2M	94.9M	109.2M	114.6M
Total Operating Expenses	113.2M	109.4M	126.6M	140.7M	161.8M	89.0M
Income Before Tax	22.0M	22.7M	(4.5M)	61.4M	70.6M	74.2M
Total Other Income Expense Net	183K	(2.6M)	(1.6M)	8.0M	9.2M	9.6M
Net Income	14.3M	12.0M	(8.6M)	35.6M	41.0M	43.0M
Income Tax Expense	7.7M	10.7M	4.1M	25.8M	29.7M	31.1M
Selling And Marketing Expenses	3.3M	2.4M	2.7M	8.5M	9.8M	6.2M
Net Income From Continuing Ops	14.3M	12.0M	(8.6M)	35.6M	41.0M	24.8M
Non Operating Income Net Other	2.9M	(7.7M)	(5.7M)	(15.5M)	(13.9M)	(13.2M)
Net Income Applicable To Common Shares	14.3M	12.0M	(8.6M)	35.6M	41.0M	24.6M
Tax Provision	7.7M	10.7M	4.1M	25.8M	29.7M	31.1M
Interest Income	2.2M	562K	560K	271K	311.7K	537.5K
Non Recurring	13.0M	11.8M	10.7M	9.5M	8.5M	13.7M
Net Interest Income	(517K)	(2.0M)	(1.1M)	(3.8M)	(3.4M)	(3.2M)
Reconciled Depreciation	4.7M	4.8M	3.8M	12.0M	13.8M	14.5M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eagle Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eagle Pharmaceuticals' short interest history, or implied volatility extrapolated from Eagle Pharmaceuticals options trading.

Pair Trading with Eagle Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eagle Stock

0.88

VRAX

Virax Biolabs Group Fiscal Year End 12th of June 2024

Pair Corr

Moving against Eagle Stock

0.64	LIXT	Lixte Biotechnology Earnings Call This Week	Pair Corr
0.49	INDP	Indaptus Therapeutics Financial Report 9th of May 2024	Pair Corr
0.48	ELVN	Enliven Therapeutics Trending	Pair Corr
0.48	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr
0.45	GBIO	Generation BioCo Financial Report 8th of May 2024	Pair Corr

The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.

The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:

How To Invest In Eagle

Details

Is Eagle Stock a good investment?

Details

What is Eagle Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.87)

Earnings Share

0.85

Revenue Per Share

19.684

Quarterly Revenue Growth

(0.13)

Return On Assets

0.0663

The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eagle Historical Income Statement

About Eagle Income Statement Analysis

Eagle Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Net Income Applicable To Common Shares

Eagle Pharmaceuticals income statement Correlations

Eagle Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eagle Pharmaceuticals income statement Accounts

Pair Trading with Eagle Pharmaceuticals

Moving together with Eagle Stock

Moving against Eagle Stock

Complementary Tools for Eagle Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Tax Provision	+ 1.0	Income Tax Expense
Other Operating Expenses	+ 0.99	Total Revenue

Net Interest Income	- 0.93	Interest Expense
Reconciled Depreciation	- 0.9	Non Operating Income Net Other
Net Interest Income	- 0.89	Selling General Administrative
Net Interest Income	- 0.89	Depreciation And Amortization
Net Interest Income	- 0.88	Cost Of Revenue
Net Interest Income	- 0.88	Other Operating Expenses